Patents by Inventor Richard E. Parker

Richard E. Parker has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20150164834
    Abstract: The present invention describes novel methods for using Treprostinil or its derivative, or a pharmaceutically acceptable salt thereof, for the treatment and/or prevention of ischemic lesions, such as digital ulcers, in subjects with scleroderma (including systemic sclerosis), Buerger's disease, Raynaud's disease, Raynaud's phenomenon and/or other conditions that cause such lesions. The invention also relates to kits for treatment and/or prevention of ischemic lesions, comprising an effective amount of Treprostinil or its derivative, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: February 24, 2015
    Publication date: June 18, 2015
    Applicant: United Therapeutics Corporation
    Inventors: Gilles Cloutier, James Crow, Michael Wade, Richard E. Parker, James E. Loyd
  • Publication number: 20130117525
    Abstract: The present invention is directed to a method for pre-emptive read reconstruction. In the method(s) disclosed herein, when a pre-emptive read reconstruction timer times out, if one or more drive read operations for providing requested stripe read data are still pending; and if stripe read data corresponding to the pending drive read operations may be constructed (ex.—reconstructed) based on the stripe read data received before the expiration of the timer, the pending drive read operations are classified as stale, but the pending drive read operations are still allowed to complete rather than being aborted, thereby promoting efficiency of the data storage system in situations when the data storage system includes an abnormal disk drive (ex.—a disk drive which endures random cycles of low read performance).
    Type: Application
    Filed: November 4, 2011
    Publication date: May 9, 2013
    Applicant: LSI CORPORATION
    Inventors: Martin Jess, Kevin Kidney, Richard E. Parker, Theresa L. Segura
  • Publication number: 20090124697
    Abstract: The present invention describes novel methods for using Treprostinil or its derivative, or a pharmaceutically acceptable salt thereof, for the treatment and/or prevention of ischemic lesions, such as digital ulcers, in subjects with scleroderma (including systemic sclerosis), Buerger's disease, Raynaud's disease, Raynaud's phenomenon and/or other conditions that cause such lesions. The invention also relates to kits for treatment and/or prevention of ischemic lesions, comprising an effective amount of Treprostinil or its derivative, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: September 19, 2008
    Publication date: May 14, 2009
    Inventors: Gilles Cloutier, James Crow, Michael Wade, Richard E. Parker, James E. Loyd
  • Patent number: 6756033
    Abstract: A method of delivering benzindene prostaglandins to a patient by inhalation is discussed. A benzindene prostaglandin known as UT-15 has unexpectedly superior results when administered by inhalation compared to parenterally administered UT-15 in sheep with induced pulmonary hypertension.
    Type: Grant
    Filed: August 6, 2002
    Date of Patent: June 29, 2004
    Assignee: United Therapeutics Corporation
    Inventors: Gilles Cloutier, James Crow, Michael Wade, Richard E. Parker, James E. Loyd
  • Publication number: 20030053958
    Abstract: A method of delivering benzindene prostaglandins to a patient by inhalation is discussed. A benzindene prostaglandin known as UT-15 has unexpectedly superior results when administered by inhalation compared to parenterally administered UT-15 in sheep with induced pulmonary hypertension.
    Type: Application
    Filed: August 6, 2002
    Publication date: March 20, 2003
    Applicant: United Therapeutics Corporation
    Inventors: Gilles Cloutier, James Crow, Michael Wade, Richard E. Parker, James E. Loyd
  • Patent number: 6521212
    Abstract: A method of delivering benzindene prostaglandins to a patient by inhalation is discussed. A benzindene prostaglandin known as UT-15 has unexpectedly superior results when administered by inhalation compared to parenterally administered UT-15 in sheep with induced pulmonary hypertension.
    Type: Grant
    Filed: March 15, 2000
    Date of Patent: February 18, 2003
    Assignee: United Therapeutics Corporation
    Inventors: Gilles Cloutier, James Crow, Michael Wade, Richard E. Parker, James E. Loyd
  • Patent number: D283004
    Type: Grant
    Filed: March 16, 1983
    Date of Patent: March 18, 1986
    Inventor: Richard E. Parker